Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma

Abstract

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been involved in the pathogenesis and progression of several cancers. However, the exact effect of MALAT1 in primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) has not been elucidated. This study aimed to explore the prognostic value of MALAT1 in PGI-DLBCL patients. Quantitative real-time Polymerase Chain Reaction (qRT-PCR) was performed to detect the expression of MALAT1 in 90 patients with PGI-DLBCL.MALAT1 was remarkably up-regulated in PGI-DLBCL tissues as compared to that of paired adjacent nontumor tissues (P<0.001), and the area under the ROC curve (AUC) was 0.838. MALAT1 expression was further increased in the non-germinal center B-cell-like (non-GCB) group, advanced stage (stages IIE-IV) group and International Prognostic Index (IPI) score (3-5) group (P=0.01, P<0.001and P<0.001, respectively). Furthermore, Kaplan-Meier analysis showed that elevated MALAT1 expression was correlated with inferior Overall survival (OS) and progression free survival (PFS) in PGI-DLBCL patients (P<0.001and P<0.001, respectively), and multivariate analysis suggested that up-regulation of MALAT1 and high IPI score (3-5) were two unfavorable prognostic factors of PGI-DLBCL. In conclusion, our results demonstrates that MALAT1 might serve as a novel prognostic biomarker and an ideal therapeutic target for PGI-DLBCL patients in the future.

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

“…Other lncRNAs with a diagnostic value and higher expression in patients with DLBCL include SBF2‐AS1, 39 NORAD, 40 NONHSAT078790 23 and NONHSAT102729. 23 LncRNAs with a prognostic value for DLBCL include SNHG12, 41 , 42 NEAT1, 43 , 44 , 45 LINC00857, 46 MALAT1, 47 , 48 HAGLROS, 49 PVT1, 50 PCAT1 51 and UCA1, 52 which were upregulated, and LincRNA‐p21, 53 which was downregulated. Most of the lncRNAs mentioned above (diagnostic/prognostic/both) are suggested to be therapeutic targets for patients with DLBCL.…”

Long non-coding RNA as a potential diagnostic biomarker in head and neck squamous cell carcinoma: A systematic review and meta-analysis

“…Several studies have found that suppressing or silencing MALAT1 can limit HNSCC growth and metastasis while also increasing HNSCC cell susceptibility to radiation and chemotherapy. However, the precise role and mechanism of MALAT1 in HNSCC are still unknown, and additional study is required to understand its function and clinical importance in HNSCC [ 90 , 92 ].…”

Long non-coding RNA MALAT1 in hematological malignancies and its clinical applications

“…[ 36 ] In patients with primary gastrointestinal DLBCL (PGI-DLBCL), MALAT1 was overexpressed in tumor tissue compared with paired adjacent non-tumor tissue; further, it was notably more highly expressed in patients with the non–germinal center B-cell–like (non-GCB) phenotype, advanced stage, and high International Prognostic Index (IPI) score. [ 37 ] In clinical samples of patients with natural-killer (NK)/T-cell lymphomas and in cell lines derived from patients with various types of these lymphomas, MALAT1 was distinctively upregulated compared with other lncRNAs in all disease subtypes. [ 38 , 39 ] In mantle cell lymphoma, MALAT1 was overrepresented in tumor tissue compared with normal B lymphocytes isolated from peripheral blood of healthy donors.…”

“…In PGI-DLBCL, elevated MALAT1 expression was correlated with inferior OS and PFS. [ 37 ] In mantle cell lymphoma, MALAT1 upregulation was associated with higher IPI and reduced OS. [ 40 ] In follicular lymphoma, high MALAT1 expression predicted shorter PFS.…”